Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First Line Metastatic Breast Cancer”

386 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 386 results

Large-scale testing (Phase 3)Looking for participantsNCT06767527
What this trial is testing

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Akeso 416
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05979220
What this trial is testing

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

Who this might be right for
Breast Cancer
Shuangyue Liu 178
Large-scale testing (Phase 3)Active Not RecruitingNCT04784715
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Who this might be right for
Breast Cancer; HER2-positive; Metastatic
AstraZeneca 1,157
Large-scale testing (Phase 3)UnknownNCT02383030
What this trial is testing

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 156
Large-scale testing (Phase 3)Active Not RecruitingNCT05374512
What this trial is testing

Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Who this might be right for
Breast Cancer
AstraZeneca 644
Large-scale testing (Phase 3)UnknownNCT04385563
What this trial is testing

Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Who this might be right for
HER2-positive Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 338
Testing effectiveness (Phase 2)Study completedNCT00356811
What this trial is testing

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT00585507
What this trial is testing

Efficacy and Safety of 500mg of Fulvestrant

Who this might be right for
Breast Cancer
Beth Israel Deaconess Medical Center 40
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Testing effectiveness (Phase 2)Study completedNCT00601159
What this trial is testing

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Who this might be right for
Metastatic Breast Cancer
Fudan University 70
Testing effectiveness (Phase 2)Study completedNCT00265733
What this trial is testing

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 48
Not applicableLooking for participantsNCT06590506
What this trial is testing

High Definition Medicine for Solid Tumors Oncology

Who this might be right for
Metastatic Solid TumorAdvanced Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III 300
Not applicableEnded earlyNCT01277133
What this trial is testing

An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Post-approval studies (Phase 4)Study completedNCT02445586
What this trial is testing

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Large-scale testing (Phase 3)Ended earlyNCT00082095
What this trial is testing

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Who this might be right for
Metastatic Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 62
Early research (Phase 1)Study completedNCT00707707
What this trial is testing

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast CancerMetastatic Breast Cancer
AstraZeneca 19
Testing effectiveness (Phase 2)Study completedNCT00691379
What this trial is testing

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 46
Not applicableUnknownNCT03442504
What this trial is testing

Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Institut Cancerologie de l'Ouest 57
Testing effectiveness (Phase 2)UnknownNCT04129996
What this trial is testing

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Early research (Phase 1)Study completedNCT00002866
What this trial is testing

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Who this might be right for
Breast CancerNeutropenia
NCIC Clinical Trials Group 50
Load More Results